Analysts expect Annovis Bio, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90 M | 12.73 M | ||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.42 M | 11.80 M | ||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16 M | 12.26 M |
Analysts expect Annovis Bio, Inc. to report earnings per share of -0.29 for Q3 26, against a range of -0.31 to -0.27. The most recent reported quarter, Q2 26, came in at -0.40, a 7.0% beat against the -0.43 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.97 | -0.43 | -0.32 | -0.32 | -0.37 | -0.39 | -0.63 | -0.40 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.60 | -0.28 | -0.36 | -0.35 | -0.32 | -0.27 | -0.39 | -0.41 | -0.27 | -0.23 | -0.23 | -0.23 | -0.15 | -0.05 | -0.40 | -0.40 | ||||||||||
| Low Estimate | -0.68 | -0.30 | -0.40 | -0.39 | -0.38 | -0.31 | -0.43 | -0.45 | -0.31 | -0.25 | -0.25 | -0.25 | -0.17 | -0.05 | -0.44 | -0.44 | ||||||||||
| Consensus Estimate | -0.64 | -0.29 | -0.38 | -0.37 | -0.35 | -0.29 | -0.41 | -0.43 | -0.29 | -0.24 | -0.24 | -0.24 | -0.16 | -0.05 | -0.42 | -0.42 |